EGFR and non-small cell lung carcinoma: The present study demonstrated that concomitant use of beta-blockers with erlotinib therapy in patients with metastatic EGFR-mutant NSCLC was associated with significantly prolonged mPFS and mOS, and that this effect was retained as an independent prognostic factor in multivariate analysis.